계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Magnolia NeuroSciences
company
About
Magnolia NeuroSciences discovers and develops drug-like small molecule therapeutics for the prevention of neuronal cell death.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $31M
- Industries
- Biotechnology,Health Care,Neuroscience,Wellness
- Founded date
- Jan 1, 2018
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$31M
Magnolia NeuroSciences has raised a total of
$31M
in funding over 2 rounds. Their latest funding was raised on
Aug 13, 2018 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 13, 2018 | Series A | $31M | 3 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
Magnolia NeuroSciences is funded by 3 investors.
ARCH Venture Partners
and Watson Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series A |
|
|
— | Series A |
Lilly Asia Ventures
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
